Added to YB: 2026-05-29
Pitch date: 2026-05-26
SLV.WA [neutral]
Selvita S.A.
Author Info
No bio for this author
Company Info
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety platform, translational research and biomarkers, and specialized discovery platform; vivo models, non-GLP toxicology, histopathology, and tissue biobank; ADME and pharmacokinetic study, bioanalysis, DMPK strategy, and modeling; and proteomic, transcriptomic, spatial mass spectrometry imaging, and data analysis services.
Market Cap
PLN 551.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.56
P/E
-143.10
EV/Sales
1.94
Sector
Life Sciences Tools and Services
Category
special_situation
KEDM Lite Vol. 15 - Selvita S.A.
SLV.WA (update): Launched strategic review post weak Q. Drug Development shows healthy growth, Drug Discovery under pressure (reflected in split backlog). Trading <10x EV/EBITDA vs 20x+ historically. Potential value unlock via Drug Discovery sale + rerating of remaining business.
Read full article (1 min)